Patents by Inventor Eric R. Schuur

Eric R. Schuur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090297483
    Abstract: Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.
    Type: Application
    Filed: November 21, 2007
    Publication date: December 3, 2009
    Applicant: Cell Genesys, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu
  • Patent number: 7319033
    Abstract: Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: January 15, 2008
    Assignee: Cell Genesys, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu
  • Patent number: 7011976
    Abstract: Replication competent adenoviral vectors specific for cells expressing alfa-fetoprotein (AFP) are provided. These replication-competetent adenoviral vectors comprise adenovirus genes essential for replication under the transcriptional control of an AFP-transcriptional regulatory element.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: March 14, 2006
    Assignee: Calydon, Inc.
    Inventors: Andrew S. Little, Henry G. Lamparski, Daniel R. Henderson, Eric R. Schuur
  • Patent number: 7001764
    Abstract: Compositions comprising host cell specific adenovirus vehicles are provided for transfecting target host cells. The compositions comprise replication competent adenovirus having an adenovirus gene essential for replication under transcriptional control of a cell type specific transcriptional response element (TRE) and polyethylene glycol (PEG) as a masking agent.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: February 21, 2006
    Assignee: Cell Genesys, Inc.
    Inventors: Andrew S. Little, Henry G. Lamparski, Daniel R. Henderson, Eric R. Schuur
  • Patent number: 6916918
    Abstract: Enhancers which preferentially increase the transcription of cis-linked coding sequences in prostate cells are provided. Methods of using DNA constructs comprising the enhancers to control transcription of heterologous polynucleotides are also provided. Delivery vehicles comprising the enhancers and methods of using the vehicles are also provided. Adenovirus vectors in which one or more genes are under transcriptional control of the enhancers of the invention are also provided. Further provided are methods of using the adenovirus vectors of the invention to confer selective cytotoxicity in mammalian cells.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: July 12, 2005
    Assignee: Cell Genesys, Inc.
    Inventors: De Chao Yu, Daniel R. Henderson, Eric R. Schuur
  • Publication number: 20040241857
    Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.
    Type: Application
    Filed: April 13, 2004
    Publication date: December 2, 2004
    Inventors: Daniel R. Henderson, Eric R. Schuur
  • Patent number: 6676935
    Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: January 13, 2004
    Assignee: Cell Genesys, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur
  • Publication number: 20030152553
    Abstract: Compositions comprising host cell specific adenovirus vehicles are provided for transfecting target host cells. The compositions comprise replication competent adenovirus having an adenovirus gene essential for replication under transcriptional control of a cell type specific transcriptional response element (TRE) and polyethylene glycol (PEG) as a masking agent.
    Type: Application
    Filed: May 2, 2002
    Publication date: August 14, 2003
    Inventors: Andrew S. Little, Henry G. Lamparski, Daniel R. Henderson, Eric R. Schuur
  • Patent number: 6585968
    Abstract: Adenovirus vectors replication specific for cells expressing &agr;-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: July 1, 2003
    Assignee: Cell Genesys, Inc.
    Inventors: Andrew S. Little, Daniel R. Henderson, Eric R. Schuur, Henry Lamparski
  • Publication number: 20030091538
    Abstract: Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.
    Type: Application
    Filed: August 16, 2002
    Publication date: May 15, 2003
    Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu
  • Publication number: 20030044383
    Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.
    Type: Application
    Filed: September 10, 1998
    Publication date: March 6, 2003
    Inventors: DANIEL R. HENDERSON, ERIC R. SCHUUR
  • Publication number: 20030039990
    Abstract: The invention provides methods and vector constructs for assaying gene expression. The vector constructs used in the invention comprise a marker which is directed to the cell surface, which in turn can be assayed. By displaying the marker protein at the cell surface, the level of activity of marker gene expression can be assessed without disrupting the cell membrane, also permitting serial measurements.
    Type: Application
    Filed: December 20, 2001
    Publication date: February 27, 2003
    Inventor: Eric R. Schuur
  • Publication number: 20030026792
    Abstract: Replication-competent adenovirus vectors specific for cells expressing carcinoembryonic antigen (CEA), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a CEA transcriptional regulatory element (CEA-TRE). The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one other adenoviral gene under control of another transcriptional regulatory element specific to cells capable of which allow a CEA-TRE to function, such as a variant of a CEA-TRE. By providing for transcriptional initiating regulation dependent upon CEA expression, virus replication can be restricted to target cells which allow a CEA-TRE to function, such as cells expressing CEA, particularly carcinoma cells capable of expressing CEA. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter gene under transcriptional control of a CEA-TRE.
    Type: Application
    Filed: October 23, 2001
    Publication date: February 6, 2003
    Inventors: Henry Lamparski, Eric R. Schuur, Daniel R. Henderson
  • Publication number: 20020164799
    Abstract: Adenovirus vectors replication specific for cells expressing &agr;-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.
    Type: Application
    Filed: July 2, 2001
    Publication date: November 7, 2002
    Inventors: Andrew S. Little, Daniel R. Henderson, Eric R. Schuur, Henry Lamparski
  • Publication number: 20020136707
    Abstract: Enhancers which preferentially increase the transcription of cis-linked coding sequences in prostate cells are provided. Methods of using DNA constructs comprising the enhancers to control transcription of heterologous polynucleotides are also provided. Delivery vehicles comprising the enhancers and methods of using the vehicles are also provided. Adenovirus vectors in which one or more genes are under transcriptional control of the enhancers of the invention are also provided. Further provided are methods of using the adenovirus vectors of the invention to confer selective cytotoxicity in mammalian cells.
    Type: Application
    Filed: June 5, 2001
    Publication date: September 26, 2002
    Inventors: De Chao Yu, Daniel R. Henderson, Eric R. Schuur
  • Patent number: 6436394
    Abstract: Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise and adenoviral gene under control of a transcription regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: August 20, 2002
    Assignee: Cell Genesys, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu
  • Publication number: 20020068049
    Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.
    Type: Application
    Filed: December 6, 2000
    Publication date: June 6, 2002
    Inventors: Daniel R. Henderson, Eric R. Schuur
  • Patent number: 6254862
    Abstract: Adenovirus vectors replication specific for cells expressing &agr;-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: July 3, 2001
    Assignee: Calydon, Inc.
    Inventors: Andrew S. Little, Daniel R. Henderson, Eric R. Schuur, Henry Lamparski
  • Patent number: 6197293
    Abstract: Replication-competent adenovirus vectors specific for cells which allows a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: March 6, 2001
    Assignee: Calydon, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu
  • Patent number: 6051417
    Abstract: Screening of compounds for activity toward inhibition of prostate cancer cell proliferation is provided. A cell line containing an expression construct comprising a transciptional initiation region of a prostate specific enhancer from a human glandular kallikrein (hKLK2) gene is employed which can be used in conventional equipment for determining activity of compounds, where the cell line uses a marker whose expression is responsive to therapeutically active compounds.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: April 18, 2000
    Assignee: Calydon, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur, Henry G. Lamparski, De-Chao Yu